# Comprehensive Cancer Center Tübingen-Stuttgart

Source: https://onco.cc/institutions/ccc-tuebingen/  
OnCo record `ccc-tuebingen` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The CCC Tübingen-Stuttgart is where Hans-Georg Rammensee's group mapped tumour-presented HLA peptides and spawned Immatics and CureVac; its dermatology clinic is one of Europe's largest melanoma centres and its imaging centre pioneered combined PET/MRI.

## Summary

The CCC Tübingen-Stuttgart is a German Cancer Aid Oncology Center of Excellence, DKTK partner site and, since 2023, part of the National Center for Tumor Diseases SouthWest. Hans-Georg Rammensee's immunology department mapped tumour-presented HLA peptides and spawned Immatics (TCR-based therapies) and, with Ingmar Hoerr, CureVac (mRNA), while the university's dermatology clinic is one of Europe's major melanoma centres. The Werner Siemens Imaging Center under Bernd Pichler pioneered combined PET/MRI, and the hospital runs large haematology, neuro-oncology and paediatric oncology programmes. Patients have access to peptide vaccine and TCR-T trials as well as molecular tumour boards.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: CCC Tübingen; Universitätsklinikum Tübingen; NCT SouthWest
- City: Tübingen, DE
- Type: cancer-center
- Website: https://www.medizin.uni-tuebingen.de/ccc

## Sources

- CCC Tübingen-Stuttgart: https://www.medizin.uni-tuebingen.de/ccc
- Universitätsklinikum Tübingen: https://www.medizin.uni-tuebingen.de
- NCT SouthWest: https://www.nct-suedwest.de

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [PET/MRI](https://onco.cc/technologies/pet-mri/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- drugs: [Afamitresgene autoleucel](https://onco.cc/drugs/afamitresgene-autoleucel/)
- companies: [Immatics](https://onco.cc/companies/immatics/)
- institutions: [Deutsches Netzwerk für Personalisierte Medizin](https://onco.cc/institutions/dnpm/), [German Cancer Consortium (DKTK)](https://onco.cc/institutions/dktk/), [German Cancer Research Center (DKFZ)](https://onco.cc/institutions/dkfz/)
- terms: [Neoantigen](https://onco.cc/terms/neoantigen/)
- people: [Lars Zender](https://onco.cc/people/lars-zender/), [Maximilian Niyazi](https://onco.cc/people/maximilian-niyazi/), [Sara Y. Brucker](https://onco.cc/people/sara-brucker/)

---
JSON: https://onco.cc/api/v1/entities/ccc-tuebingen.json